Citations

Citations to this article as recorded by  

• A bibliometric analysis of immune response in oral cancer
  Rongrong Zhang, Runying Guo, Yuqi Xin, Qingkun Jiang, Jiaxuan Qiu
  Discover Oncology.2025;[Epub]     CrossRef
• HPV frequency in oral cavity and oropharynx cancers and its association with immune checkpoint inhibitors
  Hayriye Tatlı Doğan, Mustafa Tahtacı
  Türk Tıp Dergisi.2025; 10(1): 1.     CrossRef
• Treatment Outcomes of Squamous Cell Carcinoma of the Soft Palate and the Prognostic Significance of HPV/p16 Status
  Meng‐hua Li, Xing Zhang, Feng‐jiao Li, Xian‐lu Gao, Shi‐da Yan, Qiao‐hong Lin, Xi‐yuan Li, Jian Meng, Ying Zhang, Shi‐ting Zhang, Shu‐wei Chen, Ming Song
  Head & Neck.2025;[Epub]     CrossRef
• Prognostic role of PD-L1 expression in head and neck squamous cell carcinoma: An institutional experience from India
  Pooja Sharma Kala, Naveen Thapliyal, Bhawna Pant, Nitin Sharma, Hari Shankar Pandey
  Pathology - Research and Practice.2024; 254: 155133.     CrossRef
• Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures – Principes généraux de traitement
  Béatrix Barry, Gilles Dolivet, Florian Clatot, Florence Huguet, Cyril Abdeddaim, Bertrand Baujat, Nicolas Blanchard, Gilles Calais, Xavier Carrat, Anne Chatellier, Florence Coste, Didier Cupissol, Philippe Cuvelier, Erwan De Mones Del Pujol, Sophie Deneuv
  Bulletin du Cancer.2024; 111(4): 393.     CrossRef
• PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre
  Sindhu Kilaru, Soumya Surath Panda, Lalatendu Moharana, Debahuti Mohapatra, Satya Sundar G. Mohapatra, Adyakinkar Panda, Spoorthy Kolluri, Suma Devaraj, Ananya Kabi, Bharat Das, Ghanashyam Biswas
  Journal of Cancer Research and Therapeutics.2024; 20(1): 46.     CrossRef
• Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden
  Frederico O. Gleber-Netto, Priyadharsini Nagarajan, Oded Sagiv, Curtis R. Pickering, Neil Gross, Jing Ning, Melisachew M. Yeshi, Yonas Mitku, Michael T. Tetzlaff, Bita Esmaeli
  Investigative Opthalmology & Visual Science.2024; 65(4): 24.     CrossRef
• Considerable interlaboratory variation in PD‐L1 positivity for head and neck squamous cell carcinoma in the Netherlands— A nationwide evaluation study
  Maaike Anna Hempenius, Bregje M Koomen, Ivette A G Deckers, Sjoukje F Oosting, Stefan M Willems, Bert van der Vegt
  Histopathology.2024; 85(1): 133.     CrossRef
• The Role of Estrogen and Estrogen Receptors in Head and Neck Tumors
  Jacqueline-Katrin Kranjčević, Josipa Čonkaš, Petar Ozretić
  Cancers.2024; 16(8): 1575.     CrossRef
• PD-L1 Expression and Its Association With p16 in Head and Neck Squamous Cell Carcinoma in Southwestern Uganda
  Rita Nabulya, Raymond Atwine, Brian Ssenkumba, Yekosani Mitala, Jamilah Nabukenya
  Pathology and Laboratory Medicine International.2024; Volume 16: 1.     CrossRef
• High‐risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects
  Irene Lo Cigno, Federica Calati, Carlo Girone, Marta Catozzo, Marisa Gariglio
  Journal of Medical Virology.2024;[Epub]     CrossRef
• PD-L1 immunohistochemical expression considering HPV status in oropharyngeal squamous cell carcinoma
  Raíssa Soares dos ANJOS, Marianne de Vasconcelos CARVALHO, Rayanna Thayse Florêncio COSTA, Belmiro Cavalcanti do Egito VASCONCELOS, Sandra Lúcia Dantas MORAES, Eduardo Piza PELLIZZER
  Brazilian Oral Research.2024;[Epub]     CrossRef
• PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
  Katarzyna Malinowska, Andrzej Kowalski, Anna Merecz-Sadowska, Milena Paprocka-Zjawiona, Przemysław Sitarek, Tomasz Kowalczyk, Hanna Zielińska-Bliźniewska
  Journal of Clinical Medicine.2023; 12(5): 2033.     CrossRef
• Immunotherapy in oral cancer: Review
  Despoina Papaioannou, Spyridoula Petsali, Alida Ndreou, Fani Akritidou, Vasileios Zisis, Dimitrios Kavvadas, Athanasios Poulopoulos, Sofia Karachrysafi, Dimitrios Andreadis
  Balkan Journal of Dental Medicine.2023; 27(3): 129.     CrossRef
• Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma
  Amandeep Kaur, Kristine Kuchta, William Watkin, Megan Sullivan, Lin Liu, Pouya Jamshidi, Nick Campbell, Bruce Brockstein, Ajit Paintal
  Archives of Pathology & Laboratory Medicine.2023; 147(4): 442.     CrossRef
• Expression of immune checkpoint protein in oral squamous cell carcinoma and its clinicopathological correlation: A tertiary care center cross-sectional study
  Sonal Ratnakar, Madhu Kumar, Malti K. Maurya, Sumaira Qayoom, Mala Sagar, Suresh Babu, Vijay Kumar
  Journal of Oral and Maxillofacial Pathology.2023; 27(3): 597.     CrossRef
• Commentary on “Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma”
  Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
  Open Medicine.2022; 17(1): 227.     CrossRef
• Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis
  Ramy R. Saleh, Jordan L. Scott, Nicholas Meti, Danielle Perlon, Rouhi Fazelzad, Alberto Ocana, Eitan Amir
  Molecular Diagnosis & Therapy.2022; 26(2): 153.     CrossRef
• Immunotherapy for head and neck cancer: Present and future
  Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello, Giuseppe Viscardi, Francesca Sparano, Maria Lucia Iacovino, Fernando Paragliola, Antonio Piccolo, Stefania Napolitano, Giulia Martini, Floriana Morgillo, Salvatore Cappabianca, Fortunato Ciard
  Critical Reviews in Oncology/Hematology.2022; 174: 103679.     CrossRef
• Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma
  Sebastian Blatt, Maximilian Krüger, Constantin Rump, Stefanie Zimmer, Keyvan Sagheb, Julian Künzel, Afsheen Raza
  PLOS ONE.2022; 17(5): e0269136.     CrossRef
• Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma
  Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
  Heliyon.2022; 8(10): e10667.     CrossRef
• Survival Outcomes of Complete Pulmonary Metastasectomy for Head and Neck Squamous Cell Carcinomas
  Hiroaki Kuroda, Shin Koyama, Mingyon Mun, Jun Nakajima, Kazuhito Funai, Ichiro Yoshino, Yoshikane Yamauchi, Masafumi Kawamura
  Cancer Management and Research.2022; Volume 14: 3095.     CrossRef
• Expression of PD-L1 is HPV/P16-Independent in Oral Squamous Cell Carcinoma
  Kit Kitichotkul, Nirush Lertprasertsuke, Sompid Kintarak, Surawut Pongsiriwet, Warit Powcharoen, Anak Iamaroon
  SSRN Electronic Journal .2022;[Epub]     CrossRef
• CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma
  Songtao Zhang, Qiujie Yan, Song Wei, Xiaobo Feng, Miaomiao Xue, Lina Liu, Jili Cui, Yuanyuan Zhang
  Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2021; 132(2): 202.     CrossRef
• PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis
  Yuan Qin, Jiaochen Luan, Xiang Zhou, Ying Li
  Bioscience Reports.2021;[Epub]     CrossRef
• Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
  Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei
  Expert Opinion on Biological Therapy.2021; 21(12): 1575.     CrossRef
• PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT
  Bancu Bancu, Richard Cowan, Anshuman Chaturvedi
  Archive of Clinical Cases.2021; 8(1): 14.     CrossRef
• Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
  Huanhuan Wang, Qin Zhao, Yuyu Zhang, Qihe Zhang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, Lingbin Meng, Ying Xin, Xin Jiang
  Frontiers in Immunology.2021;[Epub]     CrossRef
• The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis
  Emily Clarke, Jesper Grau Eriksen, Sarah Barrett
  Acta Oncologica.2021; 60(11): 1534.     CrossRef
• Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
  Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing H. Wang, Xiao-Jing Wang
  Communications Biology.2021;[Epub]     CrossRef
• Commentary on 'Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis' (He et al., (2020) Archives of Oral Biology, 114, 104717)
  Juan Francisco Peña-Cardelles, José Ernesto Moro-Rodríguez, José Luís Cebrián-Carretero, José Juan Pozo-Kreilinger
  Archives of Oral Biology.2021; 132: 105274.     CrossRef
• Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
  Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, We
  Cancers.2021; 13(22): 5733.     CrossRef
• Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis
  Jerry Polesel, Anna Menegaldo, Giancarlo Tirelli, Vittorio Giacomarra, Roberto Guerrieri, Lorena Baboci, Mariateresa Casarotto, Valentina Lupato, Giuseppe Fanetti, Paolo Boscolo-Rizzo, Elisabetta Fratta
  Frontiers in Oncology.2021;[Epub]     CrossRef
• Tumor Immunity and Immunotherapy for HPV-Related Cancers
  Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee, Dmitriy Zamarin, Nadeem Riaz
  Cancer Discovery.2021; 11(8): 1896.     CrossRef
• An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
  Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila, José Antonio Gil‐Montoya
  Oral Diseases.2020; 26(3): 511.     CrossRef
• A treatise on endothelial biology and exosomes: homage to Theresa Maria Listowska Whiteside
  N. Ludwig, M. T. Lotze
  HNO.2020; 68(2): 71.     CrossRef
• PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva
  Bastian Czogalla, Deborah Pham, Fabian Trillsch, Miriam Rottmann, Julia Gallwas, Alexander Burges, Sven Mahner, Thomas Kirchner, Udo Jeschke, Doris Mayr, Elisa Schmoeckel
  Journal of Cancer Research and Clinical Oncology.2020; 146(3): 569.     CrossRef
• Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking
  Jacob K. Lilja-Fischer, Jesper G. Eriksen, Jeanette B. Georgsen, Thao T. Vo, Stine R. Larsen, Jonathan Cheng, Michael Busch-Sørensen, Deepti Aurora-Garg, Torben Steiniche, Jens Overgaard
  Acta Oncologica.2020; 59(6): 666.     CrossRef
• Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment
  Lien Lippens, Mieke Van Bockstal, Emiel A. De Jaeghere, Philippe Tummers, Amin Makar, Sofie De Geyter, Koen Van de Vijver, An Hendrix, Katrien Vandecasteele, Hannelore Denys
  International Journal of Cancer.2020; 147(2): 554.     CrossRef
• Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
  Victor C. Kok
  Frontiers in Oncology.2020;[Epub]     CrossRef
• The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis
  Hui Tang, Xiang Zhou, Yu Ye, Yi Zhou, Chengyu Wu, Yan Xu
  Pathology - Research and Practice.2020; 216(1): 152768.     CrossRef
• Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis
  Jing He, Xiao-Fang Chen, Ming-Gao Xu, Jing Zhao
  Archives of Oral Biology.2020; 114: 104717.     CrossRef
• The role of transforming growth factor‐beta in immune suppression and chronic inflammation of squamous cell carcinomas
  Alexander A. Strait, Xiao‐Jing Wang
  Molecular Carcinogenesis.2020; 59(7): 745.     CrossRef
• The roles of programmed death ligand 1 in virus-associated cancers
  Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
  Infection, Genetics and Evolution.2020; 84: 104368.     CrossRef
• Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
  Yong-Xin Cui, Xian-Shuang Su
  Open Medicine.2020; 15(1): 292.     CrossRef
• The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma
  Dominik Gurin, Marek Slavik, Marketa Hermanova, Iveta Selingerova, Tomas Kazda, Michal Hendrych, Tetiana Shatokhina, Marcela Vesela
  Journal of Oral Pathology & Medicine.2020; 49(9): 886.     CrossRef
• PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma
  Nora Wuerdemann, Sibel E. Gültekin, Katharina Pütz, Claus Wittekindt, Christian U. Huebbers, Shachi J. Sharma, Hans Eckel, Anna B. Schubotz, Stefan Gattenlöhner, Reinhard Büttner, Ernst-Jan Speel, Jens P. Klussmann, Steffen Wagner, Alexander Quaas
  International Journal of Molecular Sciences.2020; 21(15): 5228.     CrossRef

• Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression

  
  Xinxin Yang, Qi You, Guodong Yao, Jingshu Geng, Rong Ma, Hongxue Meng
  Cancer Management and Research.2020; Volume 12: 6747.     CrossRef
• Prevalence of high-risk human papillomavirus and its genotype distribution in head and neck squamous cell carcinomas
  Yuil Kim, Young-Hoon Joo, Min-Sik Kim, Youn Soo Lee
  Journal of Pathology and Translational Medicine.2020; 54(5): 411.     CrossRef
• The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
  Xin-wei Qiao, Jian Jiang, Xin Pang, Mei-chang Huang, Ya-jie Tang, Xin-hua Liang, Ya-ling Tang
  Frontiers in Immunology.2020;[Epub]     CrossRef
• Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma
  Barbara Seliger, Chiara Massa, Bo Yang, Daniel Bethmann, Matthias Kappler, Alexander Walter Eckert, Claudia Wickenhauser
  International Journal of Molecular Sciences.2020; 21(19): 7032.     CrossRef
• PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
  D. Evrard, M. Hourseau, A. Couvelard, V. Paradis, H. Gauthier, E. Raymond, C. Halimi, B. Barry, S. Faivre
  OncoImmunology.2020;[Epub]     CrossRef
• Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients
  Atsumu Kouketsu, Ikuro Sato, Mariko Oikawa, Yoshinaka Shimizu, Hiroki Saito, Tetsu Takahashi, Hiroyuki Kumamoto
  Journal of Cranio-Maxillofacial Surgery.2019; 47(1): 33.     CrossRef
• The value of immunotherapy in head and neck cancer
  Paolo Manca, Luis E. Raez, Matthew Salzberg, Jorge Sanchez, Brian Hunis, Christian Rolfo
  Expert Opinion on Biological Therapy.2019; 19(1): 35.     CrossRef
• Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route
  Iacopo Panarese, Gabriella Aquino, Andrea Ronchi, Francesco Longo, Marco Montella, Immacolata Cozzolino, Giuseppe Roccuzzo, Giuseppe Colella, Michele Caraglia, Renato Franco
  Expert Review of Anticancer Therapy.2019; 19(2): 105.     CrossRef
• The Double-Edged Sword—How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer
  Hao-fan Wang, Sha-sha Wang, Ya-Jie Tang, Yu Chen, Min Zheng, Ya-ling Tang, Xin-hua Liang
  Frontiers in Immunology.2019;[Epub]     CrossRef
• The protective role of carnosic acid in ischemic/reperfusion injury through regulation of autophagy under T2DM
  Min Hu, Tianyu Li, Zixiang Bo, Feixiang Xiang
  Experimental Biology and Medicine.2019; 244(7): 602.     CrossRef
• Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
  Fabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, Lars Mortimer Schiffmann, Julian Puppe, Peter Mallmann, Stefanie Hamacher, Reinhard Buettner, Christina Alidousty, Barbara Holz, Andreas H. Scheel, Anne Maria Schultheis
  Journal of Cancer Research and Clinical Oncology.2019; 145(6): 1651.     CrossRef
• The emergence of long-term survivors in recurrent and metastatic squamous cell head and neck cancer
  Florian Castet, Jesús Brenes, Miren Taberna, Ricard Mesía
  Current Opinion in Oncology.2019; 31(3): 160.     CrossRef
• PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas
  Giuseppe Riva, Giancarlo Pecorari, Matteo Biolatti, Sara Pautasso, Irene Lo Cigno, Massimiliano Garzaro, Valentina Dell’Oste, Santo Landolfo
  Molecular Biology Reports.2019; 46(3): 3333.     CrossRef
• PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma
  Priyadharsini Nagarajan, Christian El-Hadad, Stephen K. Gruschkus, Jing Ning, Courtney W. Hudgens, Oded Sagiv, Neil Gross, Michael T. Tetzlaff, Bita Esmaeli
  Investigative Opthalmology & Visual Science.2019; 60(6): 2388.     CrossRef
• PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma
  Yui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, Takumi Kumai, Marino Nagata, Shohei Harabuchi, Akemi Kosaka, Toshihiro Nagato, Kei Ishibashi, Kensuke Oikawa, Naoko Aoki, Mizuho Ohara, Yasuaki Harabuchi, Yuji Uno, Hidehiro Takei, Esteban Celis, Hiroya Kob
  Journal of Translational Medicine.2019;[Epub]     CrossRef
• 転移・再発頭頸部がんに対する分子標的薬と免疫チェックポイント阻害薬のエビデンス
  
  Nippon Jibiinkoka Gakkai Kaiho.2019; 122(6): 848.     CrossRef
• Prognostic Value of Combined Programmed Cell Death 1 Ligand and p16 Expression Predicting Responsiveness to Radiotherapy in Patients with Oropharyngeal Squamous Cell Carcinoma
  Minsu Kwon, Dae Hwan Kim, Ki Ju Cho, Youngchul Kim, Jin Pyeong Kim, Bae Kwon Jeong, Jong Sil Lee, Ji-Hyun Seo, Jung Je Park
  Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2019; 62(12): 712.     CrossRef
• Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
  Valerie Cristina, Ruth Gabriela Herrera-Gómez, Petr Szturz, Vittoria Espeli, Marco Siano
  International Journal of Molecular Sciences.2019; 20(21): 5399.     CrossRef
• The expression of PD-L1 in salivary gland carcinomas
  Domenic Vital, Kristian Ikenberg, Holger Moch, Matthias Rössle, Gerhard F. Huber
  Scientific Reports.2019;[Epub]     CrossRef
• Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis
  Yi-Qun Jia, Bo Yang, Li-Ling Wen, Wen-Xin Mu, Zhi Wang, Bin Cheng
  Aging.2019; 11(2): 501.     CrossRef
• Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
  Nabil F. Saba, Zhuo Gerogia Chen, Missak Haigentz, Paolo Bossi, Alessandra Rinaldo, Juan P. Rodrigo, Antti A. Mäkitie, Robert P. Takes, Primoz Strojan, Jan B. Vermorken, Alfio Ferlito
  Molecular Cancer Therapeutics.2019; 18(11): 1909.     CrossRef
• PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma
  Juan C. de Vicente, Tania Rodríguez-Santamarta, Juan P. Rodrigo, Verónica Blanco-Lorenzo, Eva Allonca, Juana M. García-Pedrero
  Cancer Epidemiology, Biomarkers & Prevention.2019; 28(3): 546.     CrossRef
• Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma
  Theresa Scognamiglio, Yao-Tseng Chen
  Head and Neck Pathology.2018; 12(2): 221.     CrossRef
• The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer
  Shao Hui Huang, Brian O'Sullivan, John Waldron
  Seminars in Radiation Oncology.2018; 28(1): 17.     CrossRef
• Implications of the tumor immune microenvironment for staging and therapeutics
  Janis M Taube, Jérôme Galon, Lynette M Sholl, Scott J Rodig, Tricia R Cottrell, Nicolas A Giraldo, Alexander S Baras, Sanjay S Patel, Robert A Anders, David L Rimm, Ashley Cimino-Mathews
  Modern Pathology.2018; 31(2): 214.     CrossRef
• Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
  Benjamin Solomon, Richard J. Young, Danny Rischin
  Seminars in Cancer Biology.2018; 52: 228.     CrossRef
• Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
  Stefano Cavalieri, Licia Rivoltini, Cristiana Bergamini, Laura D. Locati, Lisa Licitra, Paolo Bossi
  Cancer Treatment Reviews.2018; 65: 78.     CrossRef
• Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition
  Mi Jung Kwon, Young-Soo Rho, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Eun Soo Kim, Bumjung Park, Mineui Hong, Kyueng-Whan Min
  Human Pathology.2018; 80: 28.     CrossRef
• The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma
  Christine Kunkle, Flavia G Rosado
  Archives of Pathology & Laboratory Medicine.2018; 142(6): 719.     CrossRef
• Genomic Landscapes of EBV-Associated Nasopharyngeal Carcinoma vs. HPV-Associated Head and Neck Cancer
  Hoi-Lam Ngan, Lan Wang, Kwok-Wai Lo, Vivian Wai Yan Lui
  Cancers.2018; 10(7): 210.     CrossRef
• PD‐1 and PD‐L1 expression in HNSCC primary cancer and related lymph node metastasis – impact on clinical outcome
  Sven Schneider, Lorenz Kadletz, Robert Wiebringhaus, Lukas Kenner, Edgar Selzer, Thorsten Füreder, Orsolya Rajky, Anna S Berghoff, Matthias Preusser, Gregor Heiduschka
  Histopathology.2018; 73(4): 573.     CrossRef
• The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
  Wei-fa Yang, May C.M. Wong, Peter J. Thomson, Kar-Yan Li, Yu-xiong Su
  Oral Oncology.2018; 86: 81.     CrossRef
• Prognostic value of PD -L1 expression in patients with primary solid tumors
  Xiao Xiang, Peng-Cheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
  Oncotarget.2018; 9(4): 5058.     CrossRef
• Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy
  Tatiana Lepikhova, Piia-Riitta Karhemo, Riku Louhimo, Bhagwan Yadav, Astrid Murumägi, Evgeny Kulesskiy, Mikko Kivento, Harri Sihto, Reidar Grénman, Stina M. Syrjänen, Olli Kallioniemi, Tero Aittokallio, Krister Wennerberg, Heikki Joensuu, Outi Monni
  Molecular Cancer Therapeutics.2018; 17(9): 2060.     CrossRef
• Immune check point inhibitors for head and neck cancer
  Naomi Kiyota
  Toukeibu Gan.2018; 44(4): 336.     CrossRef
• Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program
  Naomi Kiyota
  Journal of Japanese Society of Oral Oncology.2018; 30(4): 144.     CrossRef
• Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study
  Matthias Troeltzsch, Timothy Woodlock, Alix Pianka, Sven Otto, Markus Troeltzsch, Michael Ehrenfeld, Thomas Knösel
  Journal of Oral and Maxillofacial Surgery.2017; 75(5): 969.     CrossRef
• Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures
  Sophie Outh-Gauer, Christophe Le Tourneau, Chloé Broudin, Florian Scotte, Hélène Roussel, Stéphane Hans, Marion Mandavit, Eric Tartour, Cécile Badoual
  Annales de Pathologie.2017; 37(1): 79.     CrossRef
• Overview of Sinonasal and Ventral Skull Base Malignancy Management
  Peter F. Svider, Michael Setzen, Soly Baredes, James K. Liu, Jean Anderson Eloy
  Otolaryngologic Clinics of North America.2017; 50(2): 205.     CrossRef
• PD-L1 expression and CD8+ infiltration shows heterogeneity in Juvenile Recurrent Respiratory Papillomatosis
  Tingyu Liu, Max Greenberg, Carissa Wentland, Brandon Sepe, Sarah Bowe, Gillian Diercks, Tiffany Huynh, Mari Mino-Kenudson, Richard Schlegel, David Kodack, Cyril Benes, Jeffrey Engelman, Christopher Hartnick
  International Journal of Pediatric Otorhinolaryngo.2017;[Epub]     CrossRef
• Programmed cell death ligand 1 as a biomarker in head and neck cancer
  Sara I. Pai, William C. Faquin
  Cancer Cytopathology.2017; 125(7): 529.     CrossRef
• Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck
  Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Wouter Huvenne, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
  Oral Oncology.2017; 70: 34.     CrossRef
• Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years
  Linnea Haeggblom, Torbjörn Ramqvist, Massimo Tommasino, Tina Dalianis, Anders Näsman
  Papillomavirus Research.2017; 4: 1.     CrossRef
• The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
  Panagiotis Balermpas, Franz Rödel, Mechthild Krause, Annett Linge, Fabian Lohaus, Michael Baumann, Inge Tinhofer, Volker Budach, Ali Sak, Martin Stuschke, Eleni Gkika, Anca-Ligia Grosu, Amir Abdollahi, Jürgen Debus, Stefan Stangl, Ute Ganswindt, Claus Bel
  International Journal of Cancer.2017; 141(3): 594.     CrossRef
• Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis
  Ji Li, Ping Wang, Youliang Xu, Jung Weon Lee
  PLOS ONE.2017; 12(6): e0179536.     CrossRef
• Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients
  Feng Yang-Chun, Cheng Zhen-Zhen, Huang Yan-Chun, Ma Xiu-Min
  Medicine.2017; 96(25): e7270.     CrossRef
• Expressions of programmed death (PD)‐1 and PD‐1 ligand (PD‐L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status
  Wen Yang, Yan‐Ping Lu, Yi‐Zhou Yang, Jia‐Rui Kang, Yi‐Duo Jin, Hong‐Wei Wang
  Journal of Obstetrics and Gynaecology Research.2017; 43(10): 1602.     CrossRef
• Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
  Chiun Hsu, Se-Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen
  Journal of Clinical Oncology.2017; 35(36): 4050.     CrossRef
• Human papillomavirus-related oropharyngeal cancer
  M. Taberna, M. Mena, M.A. Pavón, L. Alemany, M.L. Gillison, R. Mesía
  Annals of Oncology.2017; 28(10): 2386.     CrossRef
• Circulating tumour cell PD-L1 test for head and neck cancers
  Arutha Kulasinghe, Liz Kenny, Chamindie Punyadeera
  Oral Oncology.2017; 75: 6.     CrossRef
• Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer
  Astrid De Meulenaere, Tijl Vermassen, Sandrine Aspeslagh, Philippe Deron, Fréderic Duprez, Debby Laukens, Jo Van Dorpe, Liesbeth Ferdinande, Sylvie Rottey
  Oncotarget.2017; 8(46): 80443.     CrossRef
• Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
  Axel Lechner, Hans Schlößer, Sacha I. Rothschild, Martin Thelen, Sabrina Reuter, Peter Zentis, Alexander Shimabukuro-Vornhagen, Sebastian Theurich, Kerstin Wennhold, Maria Garcia-Marquez, Lars Tharun, Alexander Quaas, Astrid Schauss, Jörg Isensee, Tim Huc
  Oncotarget.2017; 8(27): 44418.     CrossRef
• Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology
  Thomas Hecking, Thore Thiesler, Cynthia Schiller, Jean-Marc Lunkenheimer, Tiyasha H. Ayub, Andrea Rohr, Mateja Condic, Mignon-Denise Keyver-Paik, Rolf Fimmers, Jutta Kirfel, Walther Kuhn, Glen Kristiansen, Kirsten Kübler
  Oncotarget.2017; 8(54): 92890.     CrossRef
• Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data
  Gustavo Dix Junqueira Pinto, Luciano de Souza Viana, Cristovam Scapulatempo Neto, Sérgio Vicente Serrano
  Journal of Immunology Research.2016; 2016: 1.     CrossRef
• Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
  Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, Nicole Schechter, Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Jill Walker
  Diagnostic Pathology.2016;[Epub]     CrossRef
• Current clinical immunotherapeutic approaches for head and neck cancer
  Carolina Soto Chervin, Bruce Brockstein
  F1000Research.2016; 5: 803.     CrossRef
• PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
  Angela M Hong, Ricardo E Vilain, Sarah Romanes, Jean Yang, Elizabeth Smith, Deanna Jones, Richard A Scolyer, C Soon Lee, Mei Zhang, Barbara Rose
  Oncotarget.2016; 7(47): 77010.     CrossRef